Celator Pharmaceuticals, Inc. Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
6/11/2014 7:38:29 AM
EWING, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has completed a planned safety review and recommended that the study should continue as planned without any modifications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by